This national, multicenter, prospective registry aims to collect standardized perioperative and follow-up data on patients undergoing minimally invasive surgical management for benign prostatic obstruction (BPO) in Turkey. Procedures include transurethral resection of the prostate (TURP), holmium/thulium laser enucleation (HoLEP/ThuLEP), Rezum®, and other contemporary techniques. By prospectively recording patient characteristics, surgical details, and postoperative outcomes in a unified electronic database, the project seeks to provide high-quality real-world evidence to support clinical decision-making, guideline updates, and future hypothesis-driven sub-studies.
The ReMIUS-BPO registry is designed as a prospective, observational, multicenter cohort study under the coordination of the Minimal Invasive Urology Society. Participating centers will record preoperative, intraoperative, and postoperative data of patients undergoing minimally invasive surgery for BPO using a secure, standardized electronic case report form. Preoperative variables include demographics, comorbidities, medication history, prostate volume, and validated symptom scores (IPSS, OAB-V8). Intraoperative data include surgical technique, energy source, operative time, and complications. Postoperative follow-up will record early and late complications, catheterization time, changes in symptom scores, and re-intervention rates. The registry aims to: 1. Create a comprehensive, analyzable national dataset for BPO surgery. 2. Compare surgical outcomes between different energy sources. 3. Evaluate the impact of the learning curve on operative time. 4. Determine long-term reoperation rates. The data will serve as a platform for future hypothesis-driven studies and potential embedded randomized controlled trials.
Study Type
OBSERVATIONAL
Enrollment
10,000
Surgical management of BPO using contemporary minimally invasive procedures, including but not limited to: Transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), Thulium laser enucleation of the prostate (ThuLEP), Rezum® water vapor thermal therapy. Procedures are performed according to standard clinical practice at each participating center, with perioperative and follow-up data prospectively recorded in the MIUS registry.
Ondokuz Mayıs University
Samsun, Turkey (Türkiye)
Proportion of eligible BPO surgery patients successfully enrolled with complete baseline, perioperative, and follow-up data in the MIUS registry
Percentage of eligible patients undergoing minimally invasive surgical treatment for BPO whose data sets are complete for all predefined variables (baseline characteristics, perioperative details, and follow-up outcomes) in the national MIUS registry. Completeness is defined as ≥95% of required data fields filled for each case.
Time frame: Within 12 months after each patient's surgery date
Comparison of perioperative complication rates between surgical techniques
Proportion of patients experiencing perioperative complications (Clavien-Dindo classification) following TURP, HoLEP, ThuLEP, or Rezum®
Time frame: up to 4 weeks
Change in International Prostate Symptom Score (IPSS)
Mean change in International Prostate Symptom Score (IPSS) from baseline to 12 months in patients undergoing minimally invasive surgical treatment for benign prostatic obstruction (BPO). The IPSS ranges from 0 to 35, with higher scores indicating more severe lower urinary tract symptoms (worse outcome).
Time frame: Baseline to 12 months post-surgery
Change in maximum urinary flow rate (Qmax)
Mean difference in Qmax (mL/sec) between preoperative measurement and 12-month follow-up.
Time frame: Baseline to 12 months post-surgery
Reoperation-free survival
Proportion of patients not requiring repeat surgical intervention for BPO within 5 years after the index procedure.
Time frame: Up to 5 years post-surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.